SCHEMBL5380218

SCHEMBL5380218

Clc1ccc(-c2c(-c3ccccc3Cl)nn3c(Cl)ccnc23)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MAPT P10636 5/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
RAB9A P51151 6/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
RXFP1 Q9HBX9 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
TP53 P04637 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TSHR P16473 1/20 0.38
NFKB1 P19838 1/20 0.38
CASP3 P42574 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
SENP8 Q96LD8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5380215 0.88 NPC1 (0.62) NPC1NPSR1MAPTCCNA2CDK2
SCHEMBL5375812 0.87 NPC1 (0.45) NPC1NPSR1MAPTCCNA2CDK2
SCHEMBL5384163 0.82 NPC1 (0.44) NPC1NPSR1MAPTCCNA2CDK2
SCHEMBL25358857 0.82 MAPT (0.48) NPC1MAPTRAB9AKMT2AMEN1
SCHEMBL4842601 0.82 SRC (0.41) NPC1NPSR1RAB9AKMT2AMEN1
SCHEMBL5380008 0.80 NPC1 (0.39) NPC1NPSR1MAPTCCNA2CDK2
SCHEMBL5380347 0.80 MAPK14 (0.43) NPC1NPSR1MAPTCCNA2CDK2
SCHEMBL5617770 0.80 CNR1 (0.42) NPC1NPSR1MAPTCCNA2CDK2
SCHEMBL4833400 0.80 SRC (0.39) NPC1NPSR1RAB9AKMT2AMEN1
SCHEMBL4836399 0.79 CNR1 (0.38) NPC1NPSR1CDK2RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
EP-1594872-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF Pfizer Products Inc. (US) 2005-11-16 EP disclosed
WO-2005103052-A1 PYRAZOLO [1,5-A] PYRIMIDIN-7-ONE COMPOUNDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2005-11-03 WO disclosed
WO-2004069838-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2004-08-19 WO disclosed
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 NPC1 650/4885NPSR1 10/4885MAPT 2827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.